Irritable Bowel Syndrome Treatment Market, by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and Others), by Medical Condition (IBS-constipation and IBS-diarrhea), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies,

Irritable Bowel Syndrome Treatment Market, by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and Others), by Medical Condition (IBS-constipation and IBS-diarrhea), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet unknown. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms do not significantly affect the quality of life. However, severe symptoms are more frequent and intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or prebiotics depending on the situation.

Market Dynamics

The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable bowel syndrome (IBS), for which various companies such as Ironwood Pharmaceuticals, Inc., conduct mass workshops for educating the people to incorporate healthy food habits as a major precaution towards prevention of IBS. Moreover, major growth drivers for the irritable bowel syndrome treatment market are expected to launch various pipeline drugs for the treatment of irritable bowel syndrome during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. For instance, according to the data provided by International Foundation for Gastrointestinal Disorders, a non-profit, educational and research organization, it’s estimated that 5-10% of the population has IBS worldwide. According to the same source, stress does not cause IBS. However, because of the connection between the brain and the gut, stress can worsen or trigger the symptoms.

Key features of the study:

• This report provides an in-depth analysis of the global irritable bowel syndrome treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global irritable bowel syndrome treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global irritable bowel syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global irritable bowel syndrome treatment market

Detailed Segmentation:

• Global Irritable Bowel Syndrome Treatment Market, By Drug Type:
• Lubiprostone
• Linaclotide
• Eluxadoline
• Rifaximin
• Alosetron
• Other
• Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:
• IBS-constipation
• IBS-diarrhea
• Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Irritable Bowel Syndrome Treatment Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Abbott
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Synergy Pharma
• Mallinckrodt
• Bausch Health Companies Inc.
• Ardelyx
• Astellas Pharma Inc.
• Novartis AG
• GSK plc.
• Ironwood Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited.

“*” marked represents similar segmentation in other categories in the respective section.